Quavonlimab

Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody[1].

Product Specifications

CAS Number

[2254059-25-9]

Product Name Alternative

MK-1308

UNSPSC

12352203

Target

CTLA-4

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/quavonlimab.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

[Quavonlimab]

Molecular Weight

(144.24 kDa)

References & Citations

[1]Perets R, et al. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021;32 (3) :395-403.

Shipping Conditions

Dry Ice

Storage Conditions

Store at -80°C for 2 years

Scientific Category

Inhibitory Antibodies

Clinical Information

Phase 2

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

379103 5 mg

3,11,12-Trihydroxyspirovetiv-1 (10) -en-2-one

Ask

View Details

NB110-58359MFV450 0.1 mL

Rabbit Polyclonal TAZ/WWTR1 Antibody [mFluor Violet 450 SE]

Ask

View Details

RC206876 10 µg

TMC4 (NM_144686) Human Tagged ORF Clone

Ask

View Details

MBS516514-01 0.01 mg

ALK2 (PF197_198L), Active

Ask

View Details

MBS516514-02 0.05 mg

ALK2 (PF197_198L), Active

Ask

View Details

MBS516514-03 0.5 mg

ALK2 (PF197_198L), Active

Ask

View Details